Literature DB >> 9413421

Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage.

S C Armstrong, J R Stephans.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9413421     DOI: 10.4088/jcp.v58n1106h

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  7 in total

Review 1.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Clinical impact of fluvoxamine-mediated long QTU syndrome.

Authors:  Amir M Nia; Kristina M Dahlem; Natig Gassanov; Hansjörg Hungerbühler; Uwe Fuhr; Fikret Er
Journal:  Eur J Clin Pharmacol       Date:  2011-06-29       Impact factor: 2.953

Review 3.  Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Authors:  Trevor I Prior; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2003-03       Impact factor: 6.186

Review 4.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Authors:  D P Figgitt; K J McClellan
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 6.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

7.  Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.

Authors:  Norio Yasui-Furukori; Tsuyoshi Kondo; Kazuo Mihara; Yoshimasa Inoue; Sunao Kaneko
Journal:  Psychopharmacology (Berl)       Date:  2003-09-04       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.